212 related articles for article (PubMed ID: 31769737)
41. Cell surface chondroitin sulphate proteoglycan 4 (CSPG4) binds to the basement membrane heparan sulphate proteoglycan, perlecan, and is involved in cell adhesion.
Tang F; Lord MS; Stallcup WB; Whitelock JM
J Biochem; 2018 May; 163(5):399-412. PubMed ID: 29462330
[TBL] [Abstract][Full Text] [Related]
42. CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL.
Jordaan S; Chetty S; Mungra N; Koopmans I; van Bommel PE; Helfrich W; Barth S
Biomedicines; 2017 Jun; 5(3):. PubMed ID: 28657611
[TBL] [Abstract][Full Text] [Related]
43. Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types.
Ilieva KM; Cheung A; Mele S; Chiaruttini G; Crescioli S; Griffin M; Nakamura M; Spicer JF; Tsoka S; Lacy KE; Tutt ANJ; Karagiannis SN
Front Immunol; 2017; 8():1911. PubMed ID: 29375561
[TBL] [Abstract][Full Text] [Related]
44. Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy.
Nota SPFT; Osei-Hwedieh DO; Drum DL; Wang X; Sabbatino F; Ferrone S; Schwab JH
Front Oncol; 2022; 12():939166. PubMed ID: 36110930
[TBL] [Abstract][Full Text] [Related]
45. Furanodienone overcomes temozolomide resistance in glioblastoma through the downregulation of CSPG4-Akt-ERK signalling by inhibiting EGR1-dependent transcription.
Chen L; Liu YC; Zheng YY; Xu J; Zhang Y; Liu WL; Li ZY; Huang GD; Li WP
Phytother Res; 2019 Jun; 33(6):1736-1747. PubMed ID: 31006910
[TBL] [Abstract][Full Text] [Related]
46. Properties of two monoclonal antibodies directed against the Fc and Fab' regions of rat IgE.
Conrad DH; Studer E; Gervasoni J; Mohanakumar T
Int Arch Allergy Appl Immunol; 1983; 70(4):352-60. PubMed ID: 6186612
[TBL] [Abstract][Full Text] [Related]
47. Immunological characterization of a basement membrane-specific chondroitin sulfate proteoglycan.
McCarthy KJ; Accavitti MA; Couchman JR
J Cell Biol; 1989 Dec; 109(6 Pt 1):3187-98. PubMed ID: 2592422
[TBL] [Abstract][Full Text] [Related]
48. Chimeric immunoglobulin E reactive with tumor-associated antigen activates human Fc epsilon RI bearing cells.
Luiten RM; Warnaar SO; Schuurman J; Pasmans SG; Latour S; Daëron M; Fleuren GJ; Litvinov SV
Hum Antibodies; 1997; 8(4):169-80. PubMed ID: 9395919
[TBL] [Abstract][Full Text] [Related]
49. Harnessing Therapeutic IgE Antibodies to Re-educate Macrophages against Cancer.
Pellizzari G; Bax HJ; Josephs DH; Gotovina J; Jensen-Jarolim E; Spicer JF; Karagiannis SN
Trends Mol Med; 2020 Jun; 26(6):615-626. PubMed ID: 32470387
[TBL] [Abstract][Full Text] [Related]
50. Therapeutic Potential of Monoclonal IgA Antibodies in Allergic Diseases: Suppressive Effect of IgA on Immune Responses Induced By Re-exposure to Antigen in Sensitized Mice by Monoclonal IgE Antibody That Binds to a Different Epitope of the Same Antigen.
Yamaki K; Yoshino S
Monoclon Antib Immunodiagn Immunother; 2015 Apr; 34(2):83-9. PubMed ID: 25897605
[TBL] [Abstract][Full Text] [Related]
51. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis.
Casale TB; Bernstein IL; Busse WW; LaForce CF; Tinkelman DG; Stoltz RR; Dockhorn RJ; Reimann J; Su JQ; Fick RB; Adelman DC
J Allergy Clin Immunol; 1997 Jul; 100(1):110-21. PubMed ID: 9257795
[TBL] [Abstract][Full Text] [Related]
52. Decitabine-Mediated Upregulation of CSPG4 in Ovarian Carcinoma Cells Enables Targeting by CSPG4-Specific CAR-T Cells.
Harrer DC; Schenkel C; Berking C; Herr W; Abken H; Dörrie J; Schaft N
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291817
[TBL] [Abstract][Full Text] [Related]
53. High chondroitin sulfate proteoglycan 4 expression correlates with poor outcome in patients with breast cancer.
Hsu NC; Nien PY; Yokoyama KK; Chu PY; Hou MF
Biochem Biophys Res Commun; 2013 Nov; 441(2):514-8. PubMed ID: 24177010
[TBL] [Abstract][Full Text] [Related]
54. Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B.
Cheung LH; Zhao Y; Alvarez-Cienfuegos A; Mohamedali KA; Cao YJ; Hittelman WN; Rosenblum MG
J Exp Clin Cancer Res; 2019 Jul; 38(1):332. PubMed ID: 31362764
[TBL] [Abstract][Full Text] [Related]
55. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab.
Baudouin V; Crusiaux A; Haddad E; Schandene L; Goldman M; Loirat C; Abramowicz D
Transplantation; 2003 Aug; 76(3):459-63. PubMed ID: 12923429
[TBL] [Abstract][Full Text] [Related]
56. Comparative reactivity of human IgE to cynomolgus monkey and human effector cells and effects on IgE effector cell potency.
Saul L; Josephs DH; Cutler K; Bradwell A; Karagiannis P; Selkirk C; Gould HJ; Jones P; Spicer JF; Karagiannis SN
MAbs; 2014; 6(2):509-22. PubMed ID: 24492303
[TBL] [Abstract][Full Text] [Related]
57. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
BioDrugs; 2002; 16(5):380-6. PubMed ID: 12408744
[TBL] [Abstract][Full Text] [Related]
58. Chondroitin sulfate proteoglycan 4 enhanced melanoma motility and growth requires a cysteine in the core protein transmembrane domain.
Yang J; Price MA; Wanshura LEC; He J; Yi M; Welch DR; Li G; Conner S; Sachs J; Turley EA; McCarthy JB
Melanoma Res; 2019 Aug; 29(4):365-375. PubMed ID: 31140988
[TBL] [Abstract][Full Text] [Related]
59. CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA.
Riccardo F; Iussich S; Maniscalco L; Lorda Mayayo S; La Rosa G; Arigoni M; De Maria R; Gattino F; Lanzardo S; Lardone E; Martano M; Morello E; Prestigio S; Fiore A; Quaglino E; Zabarino S; Ferrone S; Buracco P; Cavallo F
Clin Cancer Res; 2014 Jul; 20(14):3753-62. PubMed ID: 24874834
[TBL] [Abstract][Full Text] [Related]
60. Chimeric Antigen Receptors Based on Low Affinity Mutants of FcεRI Re-direct T Cell Specificity to Cells Expressing Membrane IgE.
Ward DE; Fay BL; Adejuwon A; Han H; Ma Z
Front Immunol; 2018; 9():2231. PubMed ID: 30364107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
